آسان درمان

Biohaven has successfully tested vasopressor, a new way to fight migraines. It is Shirazi Vard  the first CGRP inhibitor in the form of an intranasal spray.

 

According to Remedium, there are now several ways to inject CGRP inhibitors into the market designed to reduce the frequency of migraines.

 

Research has shown that high doses of the drug, 10 and 20 kg, have reduced  Shirazi Vard pain intensity by 22.5% over two hours. The sensitivity to nausea and nausea decreased by 41.9-42.5%. Interestingly, the result has been maintained for a long time. Up to 48 hours of re-injection of the drug was not required.

 

It is important that the therapy has a good effect on the patients and the side effects are 80%  Shirazi Vard less. According to the developers, the spray is absolutely safe for the liver.